A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer
Cancer Chemotherapy and Pharmacology,  Clinical Article

Hida N et al. – Concurrent chemoradiotherapy (cCRT) with non–split docetaxel (D) plus cisplatin (P) was a tolerable and effective regimen, and recommended dose (RD) was 50/80mg/m2 every 4weeks.

Methods
  • Patients (aged ≤70years) with unresectable dry stage III non-small-cell lung cancer (NSCLC) and having performance status 0 or 1 and adequate organ function were eligible.
  • They received radiotherapy (60 Gy in 30 fractions) once daily starting on day 2.
  • Concurrent P (day 1; 60mg/m2 at Levels 1–3, 80mg/m2 at Level 4) and D (day 1; 30mg/m2 at Level 1, 40mg/m2 at Level 2, 50mg/m2 at Levels 3–4) were administered every 4weeks for 2–4 courses.

Results
  • Eighteen patients were enrolled (stage IIIA/IIIB, 5/13 patients).
  • Three cases of dose-limiting toxicity were observed in this study, although another 3 cases were added at Levels 2 and 3.
  • Radiotherapy was completed in 15 patients.
  • Seventeen patients received more than 2 courses of chemotherapy.
  • Neither Grade 3/4 esophagitis nor severe hematological events were observed at Levels 1–4.
  • However, dose escalation to Level 5 (P [80mg/m2], D [60mg/m2]) was stopped because the Level 5 dose was the recommended dose (RD) of chemotherapy alone for stage IIIB/IV NSCLC in Japan.
  • Therefore, the RD was determined as D50/P80mg/m2 in this cCRT.
  • The objective response rate was 89 %, and the median survival time was 23.6months.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial The Lancet, June 4, 2014    Evidence Based Medicine    Clinical Article

2 Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer Medical Oncology, June 19, 2014    Clinical Article

3 Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors Cancer Treatment Reviews, June 23, 2014    Review Article

4 Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: A meta-analysis JAMA, April 11, 2014    Evidence Based Medicine    Clinical Article

5 Reduced risk of lung cancer with metformin therapy in diabetic patients: A systematic review and meta-analysis American Journal of Epidemiology, June 17, 2014    Evidence Based Medicine    Review Article
Exclusive Author Commentary

6 Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis Lung Cancer, June 3, 2014    Clinical Article

7 ALK-positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options Cancer, May 27, 2014    Review Article

8 Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer Tumor Biology, June 9, 2014    Clinical Article

9 Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival Lung Cancer, June 27, 2014    Clinical Article

10 Global lung cancer mortality rates and trends in women Full Text Cancer Epidemiology, Biomarkers & Prevention, May 21, 2014    Free full text    Review Article

11 Effects of acupressure on fatigue of lung cancer patients undergoing chemotherapy Complementary Therapies in Medicine, June 18, 2014    Clinical Article

12 The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer British Journal of Cancer, June 17, 2014    Clinical Article

13 Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey British Journal of Cancer, June 13, 2014    Review Article

14 Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer European Journal of Cardio-Thoracic Surgery, June 17, 2014    Review Article

15 Serum CA125 level predicts prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy Medical Oncology, June 12, 2014    Review Article

16 Home kitchen ventilation, cooking fuels, and lung cancer risk in a prospective cohort of never smoking women in Shanghai, China International Journal of Cancer, June 13, 2014    Clinical Article

17 Resource use and guideline concordance in evaluation of pulmonary nodules for cancer too much and too little care JAMA Internal Medicine, June 10, 2014    Clinical Guideline    Clinical Article

18 Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) Journal of Clinical Oncology, May 29, 2014    Clinical Article

19 Diagnostic accuracy of FDG PET/CT in mediastinal lymph nodes from lung cancer European Journal of Radiology, May 30, 2014    Review Article

20 Evidence that the lung adenocarcinoma EML4–ALK fusion gene is not caused by exposure to secondhand tobacco smoke during childhood Cancer Epidemiology, Biomarkers & Prevention, June 11, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close